#cytrx

Global Kaposi Sarcoma Market Synopsis:

The Global Kaposi Sarcoma Market report is a skilful and deep analysis of the present situation and challenges. This report focuses on the key drivers, restraints, Market opportunities, threats and risks for Market major players. It makes available analysis of Market size, shares, growth, segmentation, revenue projection (USD Mn), and regional study till 2027. Analysis and discussion of important industry trends, Market size, and Market share estimates are mentioned in the report. Kaposi Sarcoma Market research document also conducts study on production capacity, consumption, import and export for all major regions across the globe.

The reliable Kaposi Sarcoma Market report offers a comprehensive overview of the global Market and contains thoughtful insights, facts, historical information, and statistically supported and industry-verified Market data. It also encompasses forecasts using a suitable set of predictions and distinct research methodologies. This industry report is a professional in-depth study on the current state of the Market. The Market report also contains the drivers and restraints for the Kaposi Sarcoma Market that are derived from SOWT analysis, and also shows what all the recent developments, product launches, joint ventures, mergers and acquisitions by the several key players and brands that are driving the Market by systemic company profiles.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-kaposi-sarcoma-market .

The Global Kaposi Sarcoma Market is expected to growing at a CAGR of 5.70% in the forecast period of 2020 to 2027.

According to market research study, Kaposi Sarcoma is a type pf cancer in which tumours of blood vessels grow below the surface of skin, mouth, nose and anus. It can spread to lungs, liver, intestines, lymph nodes, the glands that help to fight body infection. The abnormal cells of kaposi sarcoma form red, purple or brown blotches tumours of skin and these affected areas are lesions of kaposi sarcoma.

The most significant key factors driving the growth of the Global Kaposi Sarcoma Market are rising prevalence of organ transplants in the emerging markets, increasing number of patients going through organ transplant treatment, rising incidences of HIV/AIDS associated kaposi sarcoma, growing emphasis on combination therapies, reducing drug resistance rates and decreasing case fatalities ratio.

The major players covered in the Kaposi Sarcoma Market are Aphios, Bristol Myers Squibb, Cytori Therapeutics, CytRx, Eli Lilly and Company, GlaxoSmithKline plc, F-Hoffmann Roche Ltd., Johnson and Johnson Services, Inc., Merck KGaA, Pfizer Inc. among other domestic and global players.

As per the geographic analysis, North America accounts the largest market share due to availability of advanced therapies and high rate of diagnostic conditions within the region. APAC is expected to account for the largest market share over coming years for the kaposi sarcoma market due to increased number of competitors within the market finding opportunities to develop new chemotherapy agents with lower side effects.

Overview of Global Myositis Treatment Market:

Market research information of Myositis Treatment Market report analyses prime challenges faced by the Healthcare industry currently and in the coming years, which gives idea to other Market participants about the problems they may face while operating in this Market over a longer period of time. This global Market report contains all the company profiles of the major players and brands. These factors consist of but are not limited to latest trends, Market segmentation, new Market entry, industry forecasting, future directions, opportunity identification, strategic analysis and planning, target Market analysis, insights and innovation.

A quality Myositis Treatment business report has been planned with full commitment and transparency in research and analysis. The Market analysis report enlists a number of Market drivers and restraints which are derived from SWOT analysis and also provides all the CAGR projections for the historic year 2019, base year 2021, and forecast period of 2021-2028. The report puts a light on prospective and key opportunities in new geographical Market. This universal Myositis Treatment Market report broadly comprises of absolute and distinct analysis of the Market drivers and restraints, major Market players involved in this industry, exhaustive analysis of the Market segmentation, and competitive analysis of the key players.

Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-myositis-treatment-market .

The Global Myositis Treatment Market is growing with the CAGR of 4.8% in the forecast period of 2021 to 2028.

According to the market report analysis, Myositis is basically a condition which is characterized by inflammation in muscles, which can be caused by infection, injury or autoimmune disease. Two specific kinds of myositis are polymyositis and dermatomyositis. Muscle weakness, swelling and pain are common symptoms of myositis. The major causes of myositis are inflammations, viral infections and medications such as statins, cocaine and alcohol.

The most significant key factors driving the growth of the Global Myositis Treatment Market are rising geriatric population and emerging cases of muscle inflammation, rising awareness about the disease and available treatments and therapies.

The major players covered in the Myositis Treatment Market report are Corbus Pharmaceuticals Holdings, Inc, CytRx Corporation, Pfizer Inc., Novartis AG, IDERA, Inc., Genentech, Inc,  Merck & Co., Inc., AbbVie Inc., GlaxoSmithKline plc., Mallinckrodt, Bausch Health Companies Inc., Akorn Operating Company LLC, Sanofi, Promega Corporation , AstraZeneca, Amgen Inc., among others domestic and global players.

Regional analysis, North America dominates the myositis treatment market owing to the presence of well-developed healthcare infrastructure and available treatments and therapies within the region. APAC, on the other hand, is projected to observe significant amount of growth in the myositis treatment market because the steady development healthcare infrastructure and rising geriatric population.

CytRx Corporation (NASDAQ:CYTR) collapsed on Monday after data relating to its lead pivotal hit press, and the company will open on Wednesday at just $1 a share – 60% down on its Tuesday bell price. We’ll look at the data in a little more detail shortly, but the long and short of it is the drug in question failed to demonstrate any level of stat sig improvement over currently available therapies. Management, however, is claiming that a clinical hold applied earlier in the trial has impacted the data, and that a more accurate representation will come on the back of a subsequent analysis scheduled for the final quarter of the year. CytRx investors are faced with this dilemma: take a loss and drop the exposure, or hold on in the hope that the follow up analysis will reveal something that the primary analysis didn’t. Of course, it’s impossible to say with certainty which side of the question is the right thing to do. We can shed some light on the facts, however, in an attempt to make the decision a little easier for those faced with making it. Here goes.

So, the drug. It’s called aldoxorubicin and it’s a reformulation of an already well established anti cancer agent, doxorubicin. Doxorubicin is one of the most widely used cancer drugs in the world – it’s on the WHO’s list of essential medicines, and is one of the go to chemo drugs for a whole host of cancers. It works by a process called DNA intercalation, which is essentially getting in between the DNA strands and distorting them, so as to inhibit the transcription (and in turn, replication) process.

It’s got a terrible safety profile, though. It causes hair loss, nausea and pain in nearly every patient that takes it, and has a high rate of cardiovascular associated AEs, most seriously cardiomyopathy. It’s been called red death, and not just because it’s got a scarlet hue.

With aldoxorubicin, CytRx is trying to improve on the safety profile of Doxorubicin. Well, improve the highest tolerable dose is probably a better way to put it. The former has attached to it what’s called an EMCH linker, and this makes the drug bind to albumin (which circulates in the blood stream) on administration. Albumin accumulates at tumor sites, and so the theory is that by binding to it aldoxorubicin can deliver the active compound selectively and in a targeted fashion, while minimizing the impact on non cancerous cells. This allows for far higher dosing while maintaining a similar, or even improved, safety profile to doxorubicin. Phase II data supported this theory. Phase III has not.

Basically, the data that just hit press stated that across 191 progression events, there was no stat sig difference in progression free survival between an adoxorubicin arm and an arm treated with investigator’s choice therapy (one of which was doxorubicin). Both arms came in at a little over 4 months PFS. However, across a couple of other measurements (ORR, disease control) the active arm improved upon the control arm. By how much, we don’t know, but as the company reports – significantly.

At this point it’s probably worth mentioning that there has been a lot of talk surrounding what perhaps might be construed as questionable IR activity by CytRX. This author has no opinion on that, other than to say that it’s the data that matters, and there’s generally more value in following the data than there is in following behind the scenes activity – to an extent, of course.

So in this instance, the data doesn’t look good. But we have to ask why. It would be easy to say that CytRx management is spinning its response to blame the clinical hold, and that the follow up data claim is just a delay. Some outlets are claiming exactly that. The bottom line, however, is that the CytRx drug delivers a far higher dose of a drug that is only really limited in efficacy by its toxicity, and so reducing that toxicity (as adoxorubicin does) should raise efficacy. Phase III data says it doesn’t, at least in terms of PFS, but phase II suggested it did, and by a considerable margin.

So what about the initial question? Well, it comes down to risk tolerance. This was a risky exposure before the data, but it just became twice as risky. There are two ways this is going to play out. The first, that the follow up data supports the non stat sig efficacy improvement conclusion, and the company tanks. It’s got some follow up pipeline, but not enough to support a valuation that was built on adoxorubicin’s potential, even taking into account the recent decline. The second, the follow up data suggests that the clinical hold did have an impact – for reference, the company is claiming it meant that it couldn’t sufficiently follow up on nearly two thirds of the 433 enrolled patients – and CytRx recovers.

If holders are willing (financially able) to wait and see, a small scale allocation could be an interesting one come fourth quarter. If they are looking for something low risk, however, this is not the place to find it.

Aldoxorubicin…CytRx is pouring money into R&D of cancer-fighting drugs

Aldoxorubicin, DOXO-EMCH

N’-[1-[4(S)-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-2(S),5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-2-yl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide

1H-​Pyrrole-​1-​hexanoic acid, 2,​5-​dihydro-​2,​5-​dioxo-​, (2E)​-​2-​[1-​[(2S,​4S)​-​4-​[(3-​amino-​2,​3,​6-​trideoxy-​α-​L-​lyxo-…

Aldoxorubicin…CytRx is pouring money into R&D of cancer-fighting drugs

Aldoxorubicin, DOXO-EMCH

N’-[1-[4(S)-(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyloxy)-2(S),5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-2-yl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanohydrazide

CytRx is pouring money into R&D of cancer-fighting drugs

Los Angeles Times

s most promising cancer-fighting drug, aldoxorubicin, is “sort of like a…